Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Samsung Prepping For First Biosimilar Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

Samsung Bioepis' biosimilar version of Amgen's rheumatoid arthritis blockbuster Enbrel (etanercept) is set to become the firm’s first biosimilar product to hit the market, possibly being released in South Korea late this year and in Europe in the first half of next year.

You may also be interested in...

New Clinical Data Positive For Korean Biosimilars

New clinical study data have been presented to a major international meeting on Samsung Bioepis and Celltrion's major biosimilar contenders as well as Boryung Pharm's hypertension therapy, all of which are South Korean drugs carrying their developer’s ambitions of overseas market launches or expansion.

Samsung Biosimilar Lantus Filings Planned As Pipeline Progresses

Samsung's biosimilar projects seem to be progressing smoothly, with its affiliate Samsung Bioepis in the final stage of a Phase III global clinical study for SB9, its biosimilar version of Sanofi's blockbuster Lantus (insulin glargine), for which an approval filing is planned in the U.S. in the latter half of this year and in Europe early next year.

Merck’s Revised Biosimilar Strategy Poised To Deliver

The big pharma has five biosimilars in Phase III development with its partner Samsung Bioepis, and expects to file them for regulatory approval in 2015 and 2016.


Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts